XML 62 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following table summarizes the disaggregation of revenue by nature:
 Year Ended December 31,
Dollars in millions202320222021
Net product sales$43,778 $44,671 $45,055 
Alliance revenues608 742 716 
Other revenues620 746 614 
Total Revenues$45,006 $46,159 $46,385 
Schedule of Revenue by Major Customers
Gross revenue to the three largest pharmaceutical wholesalers in the U.S. as a percentage of U.S. gross revenues was as follows:
 Year Ended December 31,
 202320222021
McKesson Corporation33 %32 %32 %
Cencora, Inc. (formerly known an AmerisourceBergen Corporation)
29 %25 %25 %
Cardinal Health, Inc.23 %21 %20 %
Reconciliation of Gross Product Sales to Net Product Sales
The following table summarizes GTN adjustments:
 Year Ended December 31,
Dollars in millions202320222021
Gross product sales$73,679 $69,633 $67,897 
GTN adjustments(a)
Charge-backs and cash discounts(9,144)(7,469)(7,253)
Medicaid and Medicare rebates(13,411)(11,362)(9,374)
Other rebates, returns, discounts and adjustments(7,346)(6,131)(6,215)
Total GTN adjustments(29,901)(24,962)(22,842)
Net product sales$43,778 $44,671 $45,055 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $134 million in 2023, $229 million in 2022, and $319 million in 2021.
Disaggregation of Revenue by Product and Region
The following table summarizes the disaggregation of revenue by product and region:
 Year Ended December 31,
Dollars in millions202320222021
In-Line Products
Eliquis12,206 $11,789 $10,762 
Opdivo9,009 8,249 7,523 
Orencia3,601 3,464 3,306 
Pomalyst/Imnovid3,441 3,497 3,332 
Yervoy2,238 2,131 2,026 
Sprycel1,930 2,165 2,117 
Mature and other brands1,895 2,045 2,234 
Total In-Line Products34,320 33,340 31,300 
New Product Portfolio
Reblozyl1,008 717 551 
Opdualag627 252 — 
Abecma472 388 164 
Zeposia434 250 134 
Breyanzi364 182 87 
Camzyos231 24 — 
Sotyktu170 8 — 
Onureg168 124 73 
Inrebic110 85 74 
Augtyro1 — — 
Total New Product Portfolio3,585 2,030 1,083 
Total In-Line Products and New Product Portfolio37,905 35,370 32,383 
Recent LOE Products(a)
Revlimid6,097 9,978 12,821 
Abraxane1,004 811 1,181 
Total Recent LOE Products 7,101 10,789 14,002 
Total revenues$45,006 $46,159 $46,385 
United States$31,555 $31,828 $29,214 
International12,752 13,497 16,319 
Other(b)
699 834 852 
Total revenues$45,006 $46,159 $46,385 
(a)    Recent LOE Products include products with significant expected decline in revenue from the prior reporting period as a result of a LOE.
(b)    Other include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.